GINA 2026 Asthma Guidelines: 10 Important Updates Transforming Asthma Management

GINA 2026 Asthma Guidelines: 10 Important Updates Transforming Asthma Management

The GINA 2026 Asthma Guidelines introduce several important changes in asthma diagnosis, treatment strategies, acute exacerbation management and biologic therapies. These updates aim to improve patient safety, reduce severe asthma attacks and strengthen evidence-based clinical practice worldwide.

Asthma affects approximately 300 million people globally and contributes to nearly 1,000 deaths every day. According to the Global Initiative for Asthma (GINA), many of these deaths are preventable through timely diagnosis, appropriate anti-inflammatory treatment and improved disease management.

Table of Contents

1. Overview of the GINA 2026 Asthma Guidelines
2. Updates in Asthma Diagnosis
3. Changes in Reliever and Maintenance Therapy
4. Acute Asthma Exacerbation Management
5. New Biologic Therapies for Severe Asthma
6. RSV Prevention and Future Directions
7. Key Takeaways for Healthcare Professionals

Overview of the GINA 2026 Asthma Guidelines

The GINA 2026 Asthma Guidelines continue the organization’s commitment to improving asthma outcomes through evidence-based recommendations. The latest report places greater emphasis on patient safety, individualized treatment approaches and anti-inflammatory reliever strategies.

Several important updates focus on reducing the risk of severe exacerbations while improving treatment adherence and long-term disease control.

GINA 2026 Asthma Guidelines – Updates in Diagnosis

GINA continues to recommend the traditional bronchodilator responsiveness (BDR) criterion for asthma diagnosis in adults and children aged six years and older.

A positive bronchodilator response is defined as:

• Increase in FEV1 or FVC ≥12%
• Increase of at least 200 mL after bronchodilator administration

The updated guidelines also introduce new assessment tools that support more personalized patient management.

CAAT (Chronic Airways Assessment Test)

The CAAT questionnaire includes eight patient-centered questions designed to evaluate chronic airway health in both asthma and COPD patients.

Peds-AIRQ

This assessment tool is intended for children aged 5–11 years and evaluates symptom control as well as future exacerbation risk.

PRAM

GINA strongly recommends the Pediatric Respiratory Assessment Measure (PRAM) as an objective method for evaluating acute asthma severity in pediatric patients.

GINA 2026 Asthma Guidelines – Changes in Reliever and Maintenance Therapy

One of the most significant updates in the GINA 2026 Asthma Guidelines involves treatment strategies.

Track 1 – Preferred Pathway

As-needed low-dose ICS-formoterol remains the preferred reliever option for adults and adolescents.

This approach:

• Reduces severe exacerbation risk
• Improves adherence
• Simplifies inhaler use across treatment steps

Track 2 – Alternative Pathway

Based on findings from the BATURA study, GINA has incorporated ICS-SABA combination therapy into Step 1.

Compared with SABA-only treatment, ICS-SABA therapy significantly lowers the risk of severe asthma exacerbations.

Triple Therapy in Step 5

For patients aged 12 years and older whose asthma remains uncontrolled despite optimized medium- or high-dose ICS-LABA treatment, triple therapy using ICS-LABA-LAMA combinations may be considered.

GINA 2026 Asthma Guidelines for Acute Asthma Exacerbation Management

Acute asthma management receives substantial attention in the updated report.

New Emergency Algorithms

GINA introduces four dedicated management pathways that differentiate:

• Primary care settings
• Emergency departments
• Children under 5 years
• Patients aged 6 years and older

Exacerbations are classified into:

• Mild
• Moderate
• Severe
• Life-threatening

Updated Oxygen Targets

Supplemental oxygen is recommended only when oxygen saturation falls below 92%.

Target oxygen saturation should generally not exceed:

• 95% in adults and children aged 6 years and above
• 92% in children under 5 years

Safer SABA Dosing

GINA highlights the risk of excessive SABA use, which may contribute to lactic acidosis and diagnostic confusion.

Recommended doses include:

• Mild exacerbation: 4 inhalations
• Moderate exacerbation: 4–6 inhalations

Use of ICS-Formoterol in the Emergency Department

For mild acute asthma attacks, ICS-formoterol may be used as a reliever instead of SABA, allowing earlier anti-inflammatory intervention.

New Biologic Therapies for Severe Asthma

The GINA 2026 Asthma Guidelines expand treatment options for severe asthma.

Depemokimab

Depemokimab is a long-acting anti-IL-5 biologic administered every 26 weeks for patients aged 12 years and older with eosinophilic asthma.

Omalizumab Biosimilar

The report also includes omalizumab-igec, a biosimilar anti-IgE therapy, as a treatment option for eligible patients.

The updated guidance encourages clinicians to consider comorbidities such as:

• Atopic dermatitis
• Nasal polyps
• Chronic urticaria

when selecting biologic therapies.

RSV Prevention and Future Directions

Respiratory syncytial virus (RSV) remains a leading cause of wheezing and lower respiratory tract infections in infants.

The GINA 2026 Asthma Guidelines highlight emerging evidence supporting:

• Maternal RSV vaccination during pregnancy
• Nirsevimab administration in infants

These preventive measures may help reduce the burden of RSV-associated disease and potentially lower future asthma risk.

Key Takeaways for Healthcare Professionals

The GINA 2026 Asthma Guidelines represent a major step forward in asthma care.

Key themes include:

• Greater emphasis on anti-inflammatory reliever therapy
• More cautious SABA use
• Lower oxygen targets
• Expanded biologic treatment options
• Improved pediatric assessment tools
• Stronger focus on patient safety

Healthcare professionals should familiarize themselves with these recommendations to optimize asthma outcomes and reduce the burden of severe exacerbations.

References

Global Initiative for Asthma (GINA)

https://ginasthma.org/2026-gina-strategy-report/

World Health Organization (WHO)

https://www.who.int/news-room/fact-sheets/detail/asthma

About Vinphaco

Vinphaco is a WHO-GMP certified pharmaceutical manufacturer in Vietnam supplying injectable products, ophthalmic products, oral solid dosage forms and other healthcare solutions to international markets across Asia, Africa, the Middle East and Latin America.

For partnership opportunities, CTD dossiers or contract manufacturing inquiries, please contact our Export Department.